Abstract
During our investigation in pyrrole antibacterial area we have identified a subclass with a good potent in vitro activity against mycobacteria and fungi. We have individuated the salient structural feature and BM 212 as lead for the class. SAR studies allowed us to synthesize several analogue derivatives. Some of them revealed more active than BM 212 against mycobacteria, but they lost antifungal activity. In particular the Protection Index (PI) was very interesting for some derivatives, comparable to that of reference compounds, Isoniazid (INH), Streptomycin (SM) and Rifampin (RF). Many of the synthesized compounds revealed active against intracellular mycobacteria and they showed to be inhibitory to drug-resistant mycobacteria of clinical origin. On the base of microbiological results we have hypothesized a pharmacophore model that was also optimized. The rational design, and the evaluation of the in vitro activity against mycobacteria are described.
Current Medicinal Chemistry
Title: BM 212 and its Derivatives as a New Class of Antimycobacterial Active Agents
Volume: 9 Issue: 21
Author(s): Mariangela Biava
Affiliation:
Abstract: During our investigation in pyrrole antibacterial area we have identified a subclass with a good potent in vitro activity against mycobacteria and fungi. We have individuated the salient structural feature and BM 212 as lead for the class. SAR studies allowed us to synthesize several analogue derivatives. Some of them revealed more active than BM 212 against mycobacteria, but they lost antifungal activity. In particular the Protection Index (PI) was very interesting for some derivatives, comparable to that of reference compounds, Isoniazid (INH), Streptomycin (SM) and Rifampin (RF). Many of the synthesized compounds revealed active against intracellular mycobacteria and they showed to be inhibitory to drug-resistant mycobacteria of clinical origin. On the base of microbiological results we have hypothesized a pharmacophore model that was also optimized. The rational design, and the evaluation of the in vitro activity against mycobacteria are described.
Export Options
About this article
Cite this article as:
Biava Mariangela, BM 212 and its Derivatives as a New Class of Antimycobacterial Active Agents, Current Medicinal Chemistry 2002; 9 (21) . https://dx.doi.org/10.2174/0929867023368953
DOI https://dx.doi.org/10.2174/0929867023368953 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Rafts and Fas/CD95 Signaling in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Protein-Protein Interactions in Drug Discovery
Drug Design Reviews - Online (Discontinued) In Vivo Imaging of Apoptosis in Cancer: Potentials and Drawbacks of Molecular Probes
Current Molecular Imaging (Discontinued) Molecular Dynamics Simulations of Protein Targets Identified in Mycobacterium tuberculosis
Current Medicinal Chemistry Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1
Drug Metabolism Letters Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects
Current Pharmaceutical Design The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science Molecular Imaging Strategies for In Vivo Tracking of MicroRNAs: A Comprehensive Review
Current Medicinal Chemistry Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Systemic Delivery of Nanoformulations of Anti-cancer Drugs with Therapeutic Potency in Animal Models of Cancer
Current Cancer Therapy Reviews Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry Lamellarins, from A to Z: A Family of Anticancer Marine Pyrrole Alkaloids
Current Medicinal Chemistry - Anti-Cancer Agents The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Family of Proteins: Transcriptional Modifiers with Multi-Functional Protein Interfaces
Current Molecular Medicine Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
Current Immunology Reviews (Discontinued) Redox-Sensitive Smart Nanosystems for Drug and Gene Delivery
Current Organic Chemistry Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis
Current Genomics Expansion or Depletion of T Follicular Helper Cells During HIV Infection: Consequences for B cell Responses
Current HIV Research Pharmacophore-Based 3D-QSAR Modeling, Virtual Screening and Molecular Docking Analysis for the Detection of MERTK Inhibitors with Novel Scaffold
Combinatorial Chemistry & High Throughput Screening Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences